Nexalin Technology (NXL) Common Equity (2021 - 2026)

Nexalin Technology's Common Equity history runs 6 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 24.12% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 24.12% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 1.96% from the prior year.
• Common Equity retreated to $2.9 million in Q1 2026 per NXL's latest filing, from $3.7 million in the prior quarter.
• Across five years, Common Equity topped out at $6.4 million in Q3 2022 and bottomed at -$2.2 million in Q2 2022.
• The 5-year median for Common Equity is $3.7 million (2024), against an average of $3.2 million.
• Across the five-year window, Common Equity jumped 425.74% in 2022 and slumped 66.17% in 2024, its largest moves.
• Year by year, Common Equity stood at $5.5 million in 2022, then sank by 41.47% to $3.2 million in 2023, then grew by 14.64% to $3.7 million in 2024, then increased by 1.96% to $3.7 million in 2025, then retreated by 22.99% to $2.9 million in 2026.
• Per Business Quant, the three latest NXL Common Equity figures stand at $2.9 million (Q1 2026), $3.7 million (Q4 2025), and $4.8 million (Q3 2025).